-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 ...
T-cell-specific surface glycoprotein CD28, also known as TP44, is a single-pass type I membrane protein that contains one Ig-like V-type (immunoglobulin-like) domain. It is a key co-stimulatory ...
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune ...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
Improving risk stratification among veterans with newly diagnosed, clinically low-risk prostate cancer using the 17-gene genomic prostate score assay. This is an ASCO Meeting Abstract from the 2016 ...
WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy. The SPEARHEAD-1 trial of ...
Alpine Immune Sciences turned heads a year ago when AbbVie formed a deal with the company worth up to $805 million in milestone payments for a first-in-class lupus drug that inhibits a protein on the ...
This is a preview. Log in through your library . Abstract Programmed cell death–1 (PD-1)–targeted therapies enhance T cell responses and show efficacy in multiple cancers, but the role of ...
Recognition of antigens is prompt and specific. But should a T cell initiate an unstoppable chain reaction of destruction against the intruder? Is it an intruder at all? It all depends on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results